In 2001, a National Institute of Health consensus panel concluded that owing to a clear survival benefit by adjuvant polychemotherapy, it should be recommended to the majority of women with localized BC regardless of lymph node, menopausal, or hormone receptor status (10). The gene discussed is NR4A1; the disease is breast cancer.